[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"longevity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:longevity":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,91,123,161,202,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642258","registry-of-outcomes-of-dezawa-musecells-100642258",false,"NCT07645989","Registry of Outcomes of Dezawa MuseCells®","Inclusion Criteria:\n\n1. Received Dezawa MuseCells® as Part of Routine Clinical Care\n2. Patients ( and\u002For authorized representative) capable of providing informed consent and participating in long-term follow-up.\n3. Willingness to Complete Online Survey Assessments\n4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.\n5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.\n6. Ability to Communicate in the Registry's Supported Language\n7. Participants must be able to read and respond to registry surveys in the designated study language.\n8. Enrollment Within 12 Months of MuseCell® Administration\n\nExclusion Criteria:\n\n1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit\u002Fnon-licensed product cannot be included.\n2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.\n3. Inability to Participate in Long-Term Digital Follow-Up\n4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes\n5. History of Malignancy Diagnosed Within the Past 12 Months\n6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.\n7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality\n8. Use of Non-Licensed or Counterfeit \"Muse-like\" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.\n9. Pregnant or Actively Breastfeeding at Time of Enrollment","ALL","89 Years",{"count":18,"type":19},5000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.\n\nThe Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.",[24,25,26,27,28],"Osteoarthritis (OA)","Longevity","Wound Care","Pain","Orthopaedic",[30,31,32,33,34],"Muse Cells","stem cells","pain","wound","inflammation","RECRUITING","2026-06-11",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":19},"2026-07-01",{"date":43,"type":19},"2031-12-31",{"name":45,"class":46},"MuseCell Innovations Pte LTD","INDUSTRY",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":71,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100633575","the-effects-of-peptistrong-and-whey-on-muscle-function-in-older-adults-100633575","NCT07528469","The Effects of PeptiStrong and Whey on Muscle Function In Older Adults","The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults","Inclusion Criteria:\n\n* Men and women aged 60 to 85 years at the time of enrolment\n* Community-dwelling (living independently or with minimal assistance)\n* Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)\n* Willing and able to attend two study visits at the research facility (baseline and end of study)\n* Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days\n* Able to understand the study information and provide written informed consent\n\nExclusion Criteria:\n\n* Any known food allergy or intolerance to fava bean protein or milk protein\n* Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated\n* Yes to any of the answers on the \"Older Adult Functional Assessment Screening Questionnaire\"\n* Individuals with implanted electronic devices\n* Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention\n* Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible",true,"60 Years","85 Years",{"count":59,"type":19},80,"INTERVENTIONAL",[62],"NA","Examining the effects of PeptiStrong and protein on muscle function in older adults",[65,66,67,68,69,25,70],"Healthy Ageing","Protein Supplementation","Muscle Health","Muscle Function","Hand Grip Strength","Peptides",[72,73,74,75,25,76,77,78,79,80],"Healthy Aging","Protein supplementation","Muscle function","Physical performance","Bioactive peptides","Hand grip strength","Short performance physical battery","Nuritas","Liverpool John Moore University","2026-04-30",{"date":83,"type":39},"2026-05-06",{"date":85,"type":39},"2026-04-06",{"date":87,"type":19},"2026-10-30",{"name":89,"class":46},"Nuritas Ltd",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":55,"sex":15,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":60,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":90},"100628039","collagen-peptides-and-cellular-aging-100628039","NCT07456449","Collagen Peptides and Cellular Aging","Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults","Inclusion Criteria:\n\n* Adults aged 50-70 years; both male and female participants are eligible\n* Body mass index (BMI) 25-30 kg\u002Fm²\n* Low to moderate physical activity: not meeting current WHO recommendations (\\\u003C150 minutes\u002Fweek) or ≤2 sessions\u002Fweek structured training\n* Able to live independently and mobile in daily life\n* No regular resistance training within the past 6 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)\n* Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)\n* Acute infections or surgeries within the last 3 months\n* Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)\n* Participation in another clinical study within the last 3 months\n* Vegetarian or vegan diet (product contains animal-derived collagen)","50 Years","70 Years",{"count":101,"type":19},125,[62],"The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).\n\nMain questions it aims to answer are:\n\nDoes six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?\n\nResearchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.\n\nParticipants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation\u002Fredox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.",[25,72,105],"Biological Ageing",[107,108,109,110,111,112],"Aging","Collagen","Supplements","Patient Care","Healthspan","Cellular aging","2026-04-28",{"date":115,"type":39},"2026-05-05",{"date":117,"type":39},"2026-04-22",{"date":119,"type":19},"2028-08",{"name":121,"class":122},"University of Vienna","OTHER",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":55,"sex":15,"minAge":131,"maxAge":99,"enrollmentInfo":132,"targetDuration":4,"studyType":60,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100617729","kaempferol-absorption-and-pharmacokinetics-evaluation-100617729","NCT07322406","Kaempferol Absorption and Pharmacokinetics Evaluation","Kaempferol Absorption and Pharmacokinetics Evaluation (K.A.P.E.)","KAPE","Inclusion Criteria:\n\nAdults aged 18 to 70 years\n\n* Healthy volunteers as determined by medical history and screening assessment\n* Ability to understand the study procedures and provide informed consent\n* Willingness and ability to comply with all study procedures, including dietary restrictions, clinic visits, blood draws, urine collection, and follow-up assessments\n* Willingness to abstain from restricted foods, beverages, and supplements as specified in the study protocol during the study period\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to Kaempferol or related flavonoids\n* Pregnancy or breastfeeding\n* Presence of significant acute or chronic medical conditions that could increase risk or interfere with study outcomes, including but not limited to:\n* Active or chronic infections\n* Cancer\n* Cardiovascular disease\n* Neurological or neurodegenerative disorders\n* Metabolic or systemic inflammatory conditions\n* Use of prescription medications or supplements known to interfere with Kaempferol metabolism or pharmacokinetic assessment\n* Blood donation within 8 weeks prior to study enrollment\n* Participation in another interventional clinical study within a timeframe that could interfere with study results or participant safety\n* Any condition or circumstance that, in the judgment of the study investigator, would make participation unsafe or compromise data integrity","18 Years",{"count":133,"type":19},120,[62],"This study is a multi-site clinical trial designed to evaluate how the body absorbs and processes Kaempferol, a naturally occurring compound found in many plant-based foods. The primary purpose of the study is to measure the pharmacokinetics and biological absorption of Kaempferol in healthy adults.\n\nParticipants will receive Kaempferol and undergo scheduled blood and urine collections over a short study period. These samples will be used to measure Kaempferol levels in the body and to assess safety and tolerability. In addition, selected biological samples will be analyzed to explore molecular changes associated with Kaempferol exposure using advanced laboratory methods.\n\nThe study will be conducted at multiple research centers in the United States using a standardized protocol to ensure consistency across sites. The information collected will help improve understanding of how Kaempferol is absorbed and metabolized in humans and will support future research and regulatory evaluation.",[137,138,25,139,140],"No Disease","Mitochondria Health","Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult","Healthy Volunteers",[142,143,144,145,146,147,148,149,150],"Mitochondria","Kaempferol","KMP","Pharmacokinetics","Bioavailability","Absorption","Dietary supplement","Healthy volunteers","Multi-omics","2026-03-19",{"date":153,"type":39},"2026-03-23",{"date":155,"type":39},"2025-12-09",{"date":157,"type":19},"2027-12-22",{"name":159,"class":122},"University of Pittsburgh",3,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":55,"sex":15,"minAge":168,"maxAge":57,"enrollmentInfo":169,"targetDuration":4,"studyType":60,"phases":171,"briefSummary":172,"conditions":173,"keywords":181,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":90},"100628795","l-serine-and-strength-training-in-the-elderly-100628795","NCT07466290","L-serine and Strength Training in the Elderly","AAAging","Inclusion Criteria:\n\n* Men and women between the ages of 65 and 85\n* Mini-Mental-State \\>23\n* Independently mobile, without aids (walker, cane, etc.)\n\nExclusion Criteria:\n\n* Chronic diseases that contraindicate medical training therapy\n* Regular strength training (\\>1x\u002Fweek) in the last 6 months before confinement\n* Frailty Index ≥ 3\n* Lack of written consent to test physical performance\n* Regular use of Cortison-containing medications or Antibiotika\n* MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body\n* Non-compliance with the study protocol: \\\u003C70% of the planned L-serine administration, \\\u003C70% of the strength training","65 Years",{"count":170,"type":19},126,[62],"This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.\n\nHealthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.\n\nCognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.",[174,25,175,176,65,177,178,179,180],"Brain Health","Cognitive Performance","Strength Training Effects","Ageing","Cognition","Memory","Muscle Strength",[65,182,183,184,185,186,187,179,188,189,190,191,192,193],"Brain ageing","Older adults","L-serine supplementation","Resistance training","Cognitive function","Cognitive ageing","Hippocampus","Magnetic resonance imaging","Electroencephalography","Brain connectivity","Muscle strength","Synaptic plasticity","2026-03-06",{"date":196,"type":39},"2026-03-12",{"date":198,"type":19},"2026-03",{"date":200,"type":19},"2028-12",{"name":121,"class":122},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":209,"maxAge":57,"enrollmentInfo":210,"targetDuration":4,"studyType":60,"phases":212,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":90},"100600063","phase-2-effectiveness-of-alternative-therapies-in-maintaining-weight-loss-achieved-by-glp-1-medications-post-cessation-100600063","NCT07092618","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Existing AgelessRx patient\n* Adults (40 - 85 years of age)\n* Any sex\n* Any ethnicity\n* BMI ≥ 22 kg\u002Fm\\^2\n* Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation\n* Have lost at least 15 lbs during their GLP-1 use\n\nExclusion Criteria:\n\n* Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)\n* History of bariatric surgery\n* Use of weight-loss medications other than GLP-1s within the past 6 months\n* Age \\\u003C40 years\n* Contraindications to naltrexone, metformin, or rapamycin\n* Significant psychiatric illness that may affect participation\n* Pregnant or breastfeeding individuals","40 Years",{"count":211,"type":19},150,[213,214],"PHASE2","PHASE3","The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications.\n\nThe main questions it aims to answer are:\n\n* Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use.\n* Whether individuals discontinuing GLP-1 receptor agonist use who instead use a combination of metformin, with or without rapamycin or low-dose naltrexone, will experience less weight regain over the course of six months post-cessation than those who do not use any alternative medications.\n\nResearchers will compare the four groups: 1) control, 2) metformin, 3) metformin + rapamycin, and 4) metformin + low-dose naltrexone, to assess changes in the percentage of weight regain, metabolic indicators (e.g., HbA1c, lipid profile), and quality of life PROs, six months after cessation of GLP-1 therapy.\n\nParticipants will:\n\n* Administer the assigned intervention following a dosing and administration protocol provided by the study and medical team.\n* Complete a medical intake for overall health status, medical history and demographic information,\n* Complete patient-reported outcomes\u002Fsurveys and assessments\n* Complete blood work at baseline and every 16 weeks thereafter to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium).\n* Share data from health wearables with the research team throughout the study to improve the accuracy of evaluating activity, sleep, heart rate, and other related healthspan measures.",[25,217,218,107],"GLP-1","Geroscience",[25,107,72,217],"2025-07-28",{"date":222,"type":39},"2025-07-30",{"date":224,"type":39},"2024-12-17",{"date":226,"type":19},"2025-08",{"name":228,"class":46},"AgelessRx",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":55,"sex":15,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":90},"100544836","longevity-families-of-the-netherlands-100544836","NCT06374069","Longevity Families of the Netherlands","LOF-NL","Inclusion Criteria:\n\n* Siblings of Dutch Caucasian descent age 75+ enriched for familial longevity\n* Individuals of Dutch Caucasian descent age 75+ who are not enriched for familial longevity\n\nExclusion Criteria:\n\n\\-","75 Years",{"count":238,"type":19},600,"The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.\n\nThe purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component.",[25,241,242,107],"Familial Longevity","Extreme Longevity","2024-04-15",{"date":245,"type":39},"2024-04-18",{"date":247,"type":39},"2023-09-11",{"date":249,"type":19},"2026-12",{"name":251,"class":122},"Leiden University Medical Center"]